OrthoPediatrics (NASDAQ:KIDS) Downgraded by Wall Street Zen to Sell

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued on Friday.

KIDS has been the subject of several other research reports. Needham & Company LLC reissued a "buy" rating and issued a $42.00 price objective on shares of OrthoPediatrics in a research note on Thursday, May 8th. Lake Street Capital initiated coverage on shares of OrthoPediatrics in a research report on Monday, April 7th. They issued a "buy" rating and a $37.00 price target for the company. BTIG Research restated a "buy" rating on shares of OrthoPediatrics in a research report on Monday. Truist Financial decreased their price target on shares of OrthoPediatrics from $26.00 to $24.00 and set a "hold" rating for the company in a research report on Friday, April 11th. Finally, Piper Sandler decreased their price target on shares of OrthoPediatrics from $40.00 to $30.00 and set an "overweight" rating for the company in a research report on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $35.83.

OrthoPediatrics Price Performance

NASDAQ:KIDS traded down $0.64 on Friday, hitting $22.01. The company had a trading volume of 159,331 shares, compared to its average volume of 196,946. The stock has a market capitalization of $534.62 million, a price-to-earnings ratio of -12.58 and a beta of 1.10. The company has a current ratio of 6.19, a quick ratio of 2.99 and a debt-to-equity ratio of 0.21. The firm has a 50 day moving average of $21.58 and a two-hundred day moving average of $23.02. OrthoPediatrics has a 52 week low of $19.52 and a 52 week high of $34.77.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.13). The company had revenue of $52.41 million during the quarter, compared to the consensus estimate of $51.68 million. OrthoPediatrics had a negative net margin of 19.15% and a negative return on equity of 7.03%. On average, research analysts anticipate that OrthoPediatrics will post -0.93 earnings per share for the current year.

Institutional Investors Weigh In On OrthoPediatrics

Large investors have recently modified their holdings of the company. KLP Kapitalforvaltning AS acquired a new stake in shares of OrthoPediatrics during the fourth quarter worth $79,000. Wells Fargo & Company MN increased its position in shares of OrthoPediatrics by 31.1% during the fourth quarter. Wells Fargo & Company MN now owns 9,853 shares of the company's stock worth $228,000 after buying an additional 2,338 shares during the period. PDT Partners LLC acquired a new stake in shares of OrthoPediatrics during the first quarter worth $244,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of OrthoPediatrics by 6.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company's stock worth $246,000 after buying an additional 645 shares during the period. Finally, GAMMA Investing LLC increased its position in shares of OrthoPediatrics by 4,618.2% during the first quarter. GAMMA Investing LLC now owns 10,616 shares of the company's stock worth $261,000 after buying an additional 10,391 shares during the period. 69.05% of the stock is currently owned by institutional investors and hedge funds.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.